<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35307513</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1095-953X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>168</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Neurobiology of disease</Title>
          <ISOAbbreviation>Neurobiol Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The innate immune system stimulating cytokine GM-CSF improves learning/memory and interneuron and astrocyte brain pathology in Dp16 Down syndrome mice and improves learning/memory in wild-type mice.</ArticleTitle>
        <Pagination>
          <StartPage>105694</StartPage>
          <MedlinePgn>105694</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nbd.2022.105694</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0969-9961(22)00086-9</ELocationID>
        <Abstract>
          <AbstractText>Down syndrome (DS) is characterized by chronic neuroinflammation, peripheral inflammation, astrogliosis, imbalanced excitatory/inhibitory neuronal function, and cognitive deficits in both humans and mouse models. Suppression of inflammation has been proposed as a therapeutic approach to treating DS co-morbidities, including intellectual disability (DS/ID). Conversely, we discovered previously that treatment with the innate immune system stimulating cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), which has both pro- and anti-inflammatory activities, improved cognition and reduced brain pathology in a mouse model of Alzheimer's disease (AD), another inflammatory disorder, and improved cognition and reduced biomarkers of brain pathology in a phase II trial of humans with mild-to-moderate AD. To investigate the effects of GM-CSF treatment on DS/ID in the absence of AD, we assessed behavior and brain pathology in 12-14 month-old DS mice (Dp[16]1Yey) and their wild-type (WT) littermates, neither of which develop amyloid, and found that subcutaneous GM-CSF treatment (5 μg/day, five days/week, for five weeks) improved performance in the radial arm water maze in both Dp16 and WT mice compared to placebo. Dp16 mice also showed abnormal astrocyte morphology, increased percent area of GFAP staining in the hippocampus, clustering of astrocytes in the hippocampus, and reduced numbers of calretinin-positive interneurons in the entorhinal cortex and subiculum, and all of these brain pathologies were improved by GM-CSF treatment. These findings suggest that stimulating and/or modulating inflammation and the innate immune system with GM-CSF treatment may enhance cognition in both people with DS/ID and in the typical aging population.</AbstractText>
          <CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ahmed</LastName>
            <ForeName>Md Mahiuddin</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; University of Colorado Alzheimer's and Cognition Center, Aurora, CO 80045, USA; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Athena Ching-Jung</ForeName>
            <Initials>AC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; University of Colorado Alzheimer's and Cognition Center, Aurora, CO 80045, USA; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Elos</LastName>
            <ForeName>Mihret</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; University of Colorado Alzheimer's and Cognition Center, Aurora, CO 80045, USA; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chial</LastName>
            <ForeName>Heidi J</ForeName>
            <Initials>HJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; University of Colorado Alzheimer's and Cognition Center, Aurora, CO 80045, USA; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sillau</LastName>
            <ForeName>Stefan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; University of Colorado Alzheimer's and Cognition Center, Aurora, CO 80045, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Solano</LastName>
            <ForeName>D Adriana</ForeName>
            <Initials>DA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; University of Colorado Alzheimer's and Cognition Center, Aurora, CO 80045, USA; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Coughlan</LastName>
            <ForeName>Christina</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; University of Colorado Alzheimer's and Cognition Center, Aurora, CO 80045, USA; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aghili</LastName>
            <ForeName>Leila</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; University of Colorado Alzheimer's and Cognition Center, Aurora, CO 80045, USA; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anton</LastName>
            <ForeName>Paige</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; University of Colorado Alzheimer's and Cognition Center, Aurora, CO 80045, USA; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Markham</LastName>
            <ForeName>Neil</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; University of Colorado Alzheimer's and Cognition Center, Aurora, CO 80045, USA; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adame</LastName>
            <ForeName>Vanesa</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; University of Colorado Alzheimer's and Cognition Center, Aurora, CO 80045, USA; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gardiner</LastName>
            <ForeName>Katheleen J</ForeName>
            <Initials>KJ</Initials>
            <AffiliationInfo>
              <Affiliation>Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boyd</LastName>
            <ForeName>Timothy D</ForeName>
            <Initials>TD</Initials>
            <AffiliationInfo>
              <Affiliation>University of Colorado Alzheimer's and Cognition Center, Aurora, CO 80045, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Potter</LastName>
            <ForeName>Huntington</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; University of Colorado Alzheimer's and Cognition Center, Aurora, CO 80045, USA; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. Electronic address: Huntington.Potter@cuanschutz.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 NS048154</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AG037942</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AG071151</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neurobiol Dis</MedlineTA>
        <NlmUniqueID>9500169</NlmUniqueID>
        <ISSNLinking>0969-9961</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>83869-56-1</RegistryNumber>
          <NameOfSubstance UI="D016178">Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004314" MajorTopicYN="Y">Down Syndrome</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016178" MajorTopicYN="N">Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007107" MajorTopicYN="N">Immune System</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007395" MajorTopicYN="N">Interneurons</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Alzheimer's disease (AD)</Keyword>
        <Keyword MajorTopicYN="Y">Astrocyte</Keyword>
        <Keyword MajorTopicYN="Y">Calretinin</Keyword>
        <Keyword MajorTopicYN="Y">Cognition</Keyword>
        <Keyword MajorTopicYN="Y">Down syndrome (DS)</Keyword>
        <Keyword MajorTopicYN="Y">Dp(16)1Yey (Dp16)</Keyword>
        <Keyword MajorTopicYN="Y">Glial-fibrillary acidic protein (GFAP)</Keyword>
        <Keyword MajorTopicYN="Y">Granulocyte-macrophage colony-stimulating factor (GM-CSF)</Keyword>
        <Keyword MajorTopicYN="Y">Intellectual disability (ID)</Keyword>
        <Keyword MajorTopicYN="Y">Interneuron</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Interests. The authors declare no competing interests. Dr. Boyd was recently hired by Partner Therapeutics, the manufacturer of human recombinant GM-CSF.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2023</Year>
          <Month>6</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>5</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35307513</ArticleId>
        <ArticleId IdType="mid">NIHMS1792971</ArticleId>
        <ArticleId IdType="pmc">PMC9045510</ArticleId>
        <ArticleId IdType="doi">10.1016/j.nbd.2022.105694</ArticleId>
        <ArticleId IdType="pii">S0969-9961(22)00086-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Antonarakis SE, Lyle R, Dermitzakis ET, Reymond A, Deutsch S. Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat Rev Genet
2004;5(10):725–38. Epub
2004/10/29. doi: 10.1038/nrg1448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrg1448</ArticleId>
            <ArticleId IdType="pubmed">15510164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Opitz JM, Gilbert-Barness EF. Reflections on the pathogenesis of Down syndrome. Am J Med Genet Suppl
1990;7:38–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2149972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epstein CJ. The consequences of chromosome imbalance. Am J Med Genet Suppl
1990;7:31–7. Epub
1990/01/01. doi: 10.1002/ajmg.1320370706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajmg.1320370706</ArticleId>
            <ArticleId IdType="pubmed">2149968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapman RS, Hesketh LJ. Behavioral phenotype of individuals with Down syndrome. Ment Retard Dev Disabil Res Rev
2000;6(2):84–95. Epub
2000/07/19. doi: 10.1002/1098-2779(2000)6:2&lt;84::Aid-mrdd2&gt;3.0.Co;2-p.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1098-2779(2000)6:2&lt;84::Aid-mrdd2&gt;3.0.Co;2-p</ArticleId>
            <ArticleId IdType="pubmed">10899801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silverman W
Down syndrome: cognitive phenotype. Ment Retard Dev Disabil Res Rev
2007;13(3):228–36. Epub
2007/10/03. doi: 10.1002/mrdd.20156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mrdd.20156</ArticleId>
            <ArticleId IdType="pubmed">17910084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Head E, Lott IT, Wilcock DM, Lemere CA. Aging in Down Syndrome and the Development of Alzheimer’s Disease Neuropathology. Curr Alzheimer Res
2016;13(1):18–29. Epub
2015/12/15. doi: 10.2174/1567205012666151020114607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1567205012666151020114607</ArticleId>
            <ArticleId IdType="pmc">PMC4948181</ArticleId>
            <ArticleId IdType="pubmed">26651341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strydom A, Coppus A, Blesa R, Danek A, Fortea J, Hardy J, Levin J, Nuebling G, Rebillat AS, Ritchie C, van Duijn C, Zaman S, Zetterberg H. Alzheimer’s disease in Down syndrome: An overlooked population for prevention trials. Alzheimers Dement (N Y)
2018;4:703–13. Epub
2018/12/26. doi: 10.1016/j.trci.2018.10.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trci.2018.10.006</ArticleId>
            <ArticleId IdType="pmc">PMC6296162</ArticleId>
            <ArticleId IdType="pubmed">30581976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lott IT, Dierssen M. Cognitive deficits and associated neurological complications in individuals with Down’s syndrome. Lancet Neurol
2010;9(6):623–33. Epub
2010/05/25. doi: 10.1016/S1474-4422(10)70112-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(10)70112-5</ArticleId>
            <ArticleId IdType="pubmed">20494326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teipel SJ, Hampel H. Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer’s disease. Behav Genet
2006;36(3):405–15. Epub
2006/02/18. doi: 10.1007/s10519-006-9047-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10519-006-9047-x</ArticleId>
            <ArticleId IdType="pubmed">16485178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hartley D, Blumenthal T, Carrillo M, DiPaolo G, Esralew L, Gardiner K, Granholm AC, Iqbal K, Krams M, Lemere C, Lott I, Mobley W, Ness S, Nixon R, Potter H, Reeves R, Sabbagh M, Silverman W, Tycko B, Whitten M, Wisniewski T. Down syndrome and Alzheimer’s disease: Common pathways, common goals. Alzheimers Dement
2015;11(6):700–9. Epub
2014/12/17. doi: 10.1016/j.jalz.2014.10.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jalz.2014.10.007</ArticleId>
            <ArticleId IdType="pmc">PMC4817997</ArticleId>
            <ArticleId IdType="pubmed">25510383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lott IT, Head E. Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging
2005;26(3):383–9. Epub
2005/01/11. doi: 10.1016/j.neurobiolaging.2004.08.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.08.005</ArticleId>
            <ArticleId IdType="pubmed">15639317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snyder HM, Bain LJ, Brickman AM, Carrillo MC, Esbensen AJ, Espinosa JM, Fernandez F, Fortea J, Hartley SL, Head E, Hendrix J, Kishnani PS, Lai F, Lao P, Lemere C, Mobley W, Mufson EJ, Potter H, Zaman SH, Granholm AC, Rosas HD, Strydom A, Whitten MS, Rafii MS. Further understanding the connection between Alzheimer’s disease and Down syndrome. Alzheimers Dement
2020;16(7):1065–77. Epub
2020/06/17. doi: 10.1002/alz.12112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/alz.12112</ArticleId>
            <ArticleId IdType="pmc">PMC8865308</ArticleId>
            <ArticleId IdType="pubmed">32544310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis MAC, Spriggs A, Rodgers A, Campbell J. The Effects of a Peer-Delivered Social Skills Intervention for Adults with Comorbid Down Syndrome and Autism Spectrum Disorder. J Autism Dev Disord
2018;48(6):1869–85. Epub
2017/12/24. doi: 10.1007/s10803-017-3437-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10803-017-3437-1</ArticleId>
            <ArticleId IdType="pubmed">29274009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bittles AH, Bower C, Hussain R, Glasson EJ. The four ages of Down syndrome. Eur J Public Health
2007;17(2):221–5. Epub
2006/07/22. doi: 10.1093/eurpub/ckl103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurpub/ckl103</ArticleId>
            <ArticleId IdType="pubmed">16857692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Block A, Ahmed MM, Dhanasekaran AR, Tong S, Gardiner KJ. Sex differences in protein expression in the mouse brain and their perturbations in a model of Down syndrome. Biol Sex Differ
2015;6:24. Epub
2015/11/12. doi: 10.1186/s13293-015-0043-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13293-015-0043-9</ArticleId>
            <ArticleId IdType="pmc">PMC4640233</ArticleId>
            <ArticleId IdType="pubmed">26557979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haydar TF, Reeves RH. Trisomy 21 and early brain development. Trends Neurosci
2012;35(2):81–91. Epub
2011/12/16. doi: 10.1016/j.tins.2011.11.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tins.2011.11.001</ArticleId>
            <ArticleId IdType="pmc">PMC3273608</ArticleId>
            <ArticleId IdType="pubmed">22169531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colombo JA, Reisin HD, Jones M, Bentham C. Development of interlaminar astroglial processes in the cerebral cortex of control and Down’s syndrome human cases. Exp Neurol
2005;193(1):207–17. Epub
2005/04/09. doi: 10.1016/j.expneurol.2004.11.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2004.11.024</ArticleId>
            <ArticleId IdType="pubmed">15817279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dossi E, Vasile F, Rouach N. Human astrocytes in the diseased brain. Brain Res Bull
2018;136:139–56. Epub
2017/02/19. doi: 10.1016/j.brainresbull.2017.02.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainresbull.2017.02.001</ArticleId>
            <ArticleId IdType="pmc">PMC5766741</ArticleId>
            <ArticleId IdType="pubmed">28212850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zorrilla de San Martin J, Delabar JM, Bacci A, Potier MC. GABAergic over-inhibition, a promising hypothesis for cognitive deficits in Down syndrome. Free Radic Biol Med
2018;114:33–9. Epub
2017/10/11. doi: 10.1016/j.freeradbiomed.2017.10.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2017.10.002</ArticleId>
            <ArticleId IdType="pubmed">28993272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reiche L, Kury P, Gottle P. Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis?
Cells
2019;8(12). Epub
2019/12/11. doi: 10.3390/cells8121591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells8121591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rissman RA, Mobley WC. Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer’s disease. J Neurochem
2011;117(4):613–22. Epub
2011/03/11. doi: 10.1111/j.1471-4159.2011.07237.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.2011.07237.x</ArticleId>
            <ArticleId IdType="pmc">PMC3127285</ArticleId>
            <ArticleId IdType="pubmed">21388375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reynolds GP, Warner CE. Amino acid neurotransmitter deficits in adult Down’s syndrome brain tissue. Neurosci Lett
1988;94(1–2):224–7. Epub 1988/11/22. doi: 10.1016/0304-3940(88)90299-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0304-3940(88)90299-6</ArticleId>
            <ArticleId IdType="pubmed">2907377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta M, Dhanasekaran AR, Gardiner KJ. Mouse models of Down syndrome: gene content and consequences. Mamm Genome
2016;27(11–12):538–55. Epub
2016/08/20. doi: 10.1007/s00335-016-9661-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00335-016-9661-8</ArticleId>
            <ArticleId IdType="pmc">PMC5471624</ArticleId>
            <ArticleId IdType="pubmed">27538963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Che M, Yuan J, Yu Y, Cao C, Qin XY, Cheng Y. Aberrations in circulating inflammatory cytokine levels in patients with Down syndrome: a meta-analysis. Oncotarget
2017;8(48):84489–96. Epub
2017/11/16. doi: 10.18632/oncotarget.21060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.21060</ArticleId>
            <ArticleId IdType="pmc">PMC5663613</ArticleId>
            <ArticleId IdType="pubmed">29137441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sullivan KD, Lewis HC, Hill AA, Pandey A, Jackson LP, Cabral JM, Smith KP, Liggett LA, Gomez EB, Galbraith MD, DeGregori J, Espinosa JM. Trisomy 21 consistently activates the interferon response. Elife
2016;5. Epub
2016/07/30. doi: 10.7554/eLife.16220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.16220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sullivan KD, Evans D, Pandey A, Hraha TH, Smith KP, Markham N, Rachubinski AL, Wolter-Warmerdam K, Hickey F, Espinosa JM, Blumenthal T. Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation. Sci Rep
2017;7(1):14818. Epub
2017/11/03. doi: 10.1038/s41598-017-13858-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-13858-3</ArticleId>
            <ArticleId IdType="pmc">PMC5665944</ArticleId>
            <ArticleId IdType="pubmed">29093484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huggard D, Doherty DG, Molloy EJ. Immune Dysregulation in Children With Down Syndrome. Front Pediatr
2020;8:73. Epub
2020/03/17. doi: 10.3389/fped.2020.00073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fped.2020.00073</ArticleId>
            <ArticleId IdType="pmc">PMC7056667</ArticleId>
            <ArticleId IdType="pubmed">32175298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huggard D, Kelly L, Ryan E, McGrane F, Lagan N, Roche E, Balfe J, Leahy TR, Franklin O, Doherty DG, Molloy EJ. Increased systemic inflammation in children with Down syndrome. Cytokine
2020;127:154938. Epub
2019/12/01. doi: 10.1016/j.cyto.2019.154938.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2019.154938</ArticleId>
            <ArticleId IdType="pubmed">31785499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flores-Aguilar L, Iulita MF, Kovecses O, Torres MD, Levi SM, Zhang Y, Askenazi M, Wisniewski T, Busciglio J, Cuello AC. Evolution of neuroinflammation across the lifespan of individuals with Down syndrome. Brain
2020. Epub
2020/11/19. doi: 10.1093/brain/awaa326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awaa326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed MM, Sturgeon X, Ellison M, Davisson MT, Gardiner KJ. Loss of correlations among proteins in brains of the Ts65Dn mouse model of down syndrome. J Proteome Res
2012;11(2):1251–63. Epub
2012/01/05. doi: 10.1021/pr2011582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/pr2011582</ArticleId>
            <ArticleId IdType="pubmed">22214338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spellman C, Ahmed MM, Dubach D, Gardiner KJ. Expression of trisomic proteins in Down syndrome model systems. Gene
2013;512(2):219–25. Epub
2012/10/30. doi: 10.1016/j.gene.2012.10.051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2012.10.051</ArticleId>
            <ArticleId IdType="pubmed">23103828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed MM, Dhanasekaran AR, Tong S, Wiseman FK, Fisher EM, Tybulewicz VL, Gardiner KJ. Protein profiles in Tc1 mice implicate novel pathway perturbations in the Down syndrome brain. Hum Mol Genet
2013;22(9):1709–24. Epub
2013/01/26. doi: 10.1093/hmg/ddt017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddt017</ArticleId>
            <ArticleId IdType="pmc">PMC3613160</ArticleId>
            <ArticleId IdType="pubmed">23349361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Araya P, Waugh KA, Sullivan KD, Núñez NG, Roselli E, Smith KP, Granrath RE, Rachubinski AL, Enriquez Estrada B, Butcher ET, Minter R, Tuttle KD, Bruno TC, Maccioni M, Espinosa JM. Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity. Proc Natl Acad Sci U S A
2019;116(48):24231–41. Epub
2019/11/09. doi: 10.1073/pnas.1908129116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1908129116</ArticleId>
            <ArticleId IdType="pmc">PMC6883781</ArticleId>
            <ArticleId IdType="pubmed">31699819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powers RK, Culp-Hill R, Ludwig MP, Smith KP, Waugh KA, Minter R, Tuttle KD, Lewis HC, Rachubinski AL, Granrath RE, Carmona-Iragui M, Wilkerson RB, Kahn DE, Joshi M, Lleó A, Blesa R, Fortea J, D’Alessandro A, Costello JC, Sullivan KD, Espinosa JM. Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors. Nat Commun
2019;10(1):4766. Epub
2019/10/20. doi: 10.1038/s41467-019-12739-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-12739-9</ArticleId>
            <ArticleId IdType="pmc">PMC6800452</ArticleId>
            <ArticleId IdType="pubmed">31628327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Y, Hong W, Wang X, Zhang P, Körner H, Tu J, Wei W. MicroRNAs in Microglia: How do MicroRNAs Affect Activation, Inflammation, Polarization of Microglia and Mediate the Interaction Between Microglia and Glioma?
Front Mol Neurosci
2019;12:125. Epub
2019/05/28. doi: 10.3389/fnmol.2019.00125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnmol.2019.00125</ArticleId>
            <ArticleId IdType="pmc">PMC6522842</ArticleId>
            <ArticleId IdType="pubmed">31133802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rachubinski AL, Estrada BE, Norris D, Dunnick CA, Boldrick JC, Espinosa JM. Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata. JAAD Case Rep
2019;5(4):365–7. Epub
2019/04/23. doi: 10.1016/j.jdcr.2019.02.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jdcr.2019.02.007</ArticleId>
            <ArticleId IdType="pmc">PMC6453941</ArticleId>
            <ArticleId IdType="pubmed">31008170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boyd TD, Bennett SP, Mori T, Governatori N, Runfeldt M, Norden M, Padmanabhan J, Neame P, Wefes I, Sanchez-Ramos J, Arendash GW, Potter H. GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice. Journal of Alzheimer’s disease : JAD
2010;21(2):507–18. doi: 10.3233/JAD-2010-091471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-2010-091471</ArticleId>
            <ArticleId IdType="pmc">PMC5588158</ArticleId>
            <ArticleId IdType="pubmed">20555144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varga-Medveczky Z, Kovács N, Tóth ME, Sántha M, Horváth I, Bors LA, Fónagy K, Imre T, Szabó P, Máthé D, Erdő F. Age-Related Inflammatory Balance Shift, Nasal Barrier Function, and Cerebro-Morphological Status in Healthy and Diseased Rodents. Front Neurosci
2021;15:700729. Epub
2021/08/10. doi: 10.3389/fnins.2021.700729.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2021.700729</ArticleId>
            <ArticleId IdType="pmc">PMC8343234</ArticleId>
            <ArticleId IdType="pubmed">34366780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmitz M, Hermann P, Oikonomou P, Stoeck K, Ebert E, Poliakova T, Schmidt C, Llorens F, Zafar S, Zerr I. Cytokine profiles and the role of cellular prion protein in patients with vascular dementia and vascular encephalopathy. Neurobiol Aging
2015;36(9):2597–606. Epub
2015/07/15. doi: 10.1016/j.neurobiolaging.2015.05.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.05.013</ArticleId>
            <ArticleId IdType="pubmed">26170132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhattacharya P, Budnick I, Singh M, Thiruppathi M, Alharshawi K, Elshabrawy H, Holterman MJ, Prabhakar BS. Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy. J Interferon Cytokine Res
2015;35(8):585–99. Epub
2015/03/25. doi: 10.1089/jir.2014.0149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/jir.2014.0149</ArticleId>
            <ArticleId IdType="pmc">PMC4529096</ArticleId>
            <ArticleId IdType="pubmed">25803788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ridwan S, Bauer H, Frauenknecht K, von Pein H, Sommer CJ. Distribution of granulocyte-monocyte colony-stimulating factor and its receptor α-subunit in the adult human brain with specific reference to Alzheimer’s disease. J Neural Transm (Vienna)
2012;119(11):1389–406. Epub
2012/03/21. doi: 10.1007/s00702-012-0794-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00702-012-0794-y</ArticleId>
            <ArticleId IdType="pubmed">22430742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borriello F, Galdiero MR, Varricchi G, Loffredo S, Spadaro G, Marone G. Innate Immune Modulation by GM-CSF and IL-3 in Health and Disease. Int J Mol Sci
2019;20(4). Epub
2019/02/17. doi: 10.3390/ijms20040834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20040834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonaventura A, Vecchié A, Wang TS, Lee E, Cremer PC, Carey B, Rajendram P, Hudock KM, Korbee L, Van Tassell BW, Dagna L, Abbate A. Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies. Front Immunol
2020;11:1625. Epub
2020/07/29. doi: 10.3389/fimmu.2020.01625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.01625</ArticleId>
            <ArticleId IdType="pmc">PMC7348297</ArticleId>
            <ArticleId IdType="pubmed">32719685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manczak M, Mao P, Nakamura K, Bebbington C, Park B, Reddy PH. Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1–42 and suppresses microglial activity in a transgenic mouse model of Alzheimer’s disease. Hum Mol Genet
2009;18(20):3876–93. Epub
2009/07/21. doi: 10.1093/hmg/ddp331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddp331</ArticleId>
            <ArticleId IdType="pmc">PMC2748895</ArticleId>
            <ArticleId IdType="pubmed">19617638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiyota T, Machhi J, Lu Y, Dyavarshetty B, Nemati M, Yokoyama I, Mosley RL, Gendelman HE. Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimer’s disease mice. J Neuroimmunol
2018;319:80–92. Epub
2018/03/27. doi: 10.1016/j.jneuroim.2018.03.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2018.03.009</ArticleId>
            <ArticleId IdType="pmc">PMC5916331</ArticleId>
            <ArticleId IdType="pubmed">29573847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castellano JM, Mosher KI, Abbey RJ, McBride AA, James ML, Berdnik D, Shen JC, Zou B, Xie XS, Tingle M, Hinkson IV, Angst MS, Wyss-Coray T. Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. Nature
2017;544(7651):488–92. Epub
2017/04/21. doi: 10.1038/nature22067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature22067</ArticleId>
            <ArticleId IdType="pmc">PMC5586222</ArticleId>
            <ArticleId IdType="pubmed">28424512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jim HS, Boyd TD, Booth-Jones M, Pidala J, Potter H. Granulocyte Macrophage Colony Stimulating Factor Treatment is Associated with Improved Cognition in Cancer Patients. Brain disorders &amp; therapy
2012;1(1). doi: 10.4172/bdt.1000101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4172/bdt.1000101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Potter H, Woodcock JH, Boyd TD, Coughlan CM, O’Shaughnessy JR, Borges MT, Thaker AA, Raj BA, Adamszuk K, Scott D, Adame V, Anton P, Chial HJ, Gray H, Daniels J, Stocker ME, Sillau SH. Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer’s disease. Alzheimers Dement (N Y)
2021;7(1):e12158. Epub
2021/03/30. doi: 10.1002/trc2.12158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/trc2.12158</ArticleId>
            <ArticleId IdType="pmc">PMC7988877</ArticleId>
            <ArticleId IdType="pubmed">33778150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reeves RH, Irving NG, Moran TH, Wohn A, Kitt C, Sisodia SS, Schmidt C, Bronson RT, Davisson MT. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet
1995;11(2):177–84. Epub
1995/10/01. doi: 10.1038/ng1095-177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng1095-177</ArticleId>
            <ArticleId IdType="pubmed">7550346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Z, Yu T, Morishima M, Pao A, LaDuca J, Conroy J, Nowak N, Matsui S, Shiraishi I, Yu YE. Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities. Hum Mol Genet
2007;16(11):1359–66. Epub
2007/04/07. doi: 10.1093/hmg/ddm086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddm086</ArticleId>
            <ArticleId IdType="pubmed">17412756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jankowsky JL, Younkin LH, Gonzales V, Fadale DJ, Slunt HH, Lester HA, Younkin SG, Borchelt DR. Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice. J Biol Chem
2007;282(31):22707–20. Epub
2007/06/09. doi: 10.1074/jbc.M611050200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M611050200</ArticleId>
            <ArticleId IdType="pmc">PMC4435736</ArticleId>
            <ArticleId IdType="pubmed">17556372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc
2006;1(4):1671–9. Epub
2007/05/10. doi: 10.1038/nprot.2006.275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nprot.2006.275</ArticleId>
            <ArticleId IdType="pubmed">17487150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faizi M, Bader PL, Tun C, Encarnacion A, Kleschevnikov A, Belichenko P, Saw N, Priestley M, Tsien RW, Mobley WC, Shamloo M. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of beta1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol Dis
2011;43(2):397–413. Epub
2011/04/30. doi: 10.1016/j.nbd.2011.04.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nbd.2011.04.011</ArticleId>
            <ArticleId IdType="pmc">PMC3539757</ArticleId>
            <ArticleId IdType="pubmed">21527343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Owen JL, Torroella-Kouri M, Handel-Fernandez ME, Iragavarapu-Charyulu V. GM-CSF up-regulates the expression of CCL2 by T lymphocytes in mammary tumor-bearing mice. Int J Mol Med
2007;20(1):129–36. Epub
2007/06/06.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17549399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fleetwood AJ, Lawrence T, Hamilton JA, Cook AD. Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J Immunol
2007;178(8):5245–52. Epub
2007/04/04. doi: 10.4049/jimmunol.178.8.5245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.178.8.5245</ArticleId>
            <ArticleId IdType="pubmed">17404308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perry JC, Pakkenberg B, Vann SD. Striking reduction in neurons and glial cells in anterior thalamic nuclei of older patients with Down syndrome. Neurobiol Aging
2019;75:54–61. Epub
2018/12/15. doi: 10.1016/j.neurobiolaging.2018.11.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.11.009</ArticleId>
            <ArticleId IdType="pmc">PMC6357872</ArticleId>
            <ArticleId IdType="pubmed">30550978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lockrow JP, Fortress AM, Granholm AC. Age-related neurodegeneration and memory loss in down syndrome. Curr Gerontol Geriatr Res
2012;2012:463909. Epub
2012/05/01. doi: 10.1155/2012/463909.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2012/463909</ArticleId>
            <ArticleId IdType="pmc">PMC3318235</ArticleId>
            <ArticleId IdType="pubmed">22545043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huo HQ, Qu ZY, Yuan F, Ma L, Yao L, Xu M, Hu Y, Ji J, Bhattacharyya A, Zhang SC, Liu Y. Modeling Down Syndrome with Patient iPSCs Reveals Cellular and Migration Deficits of GABAergic Neurons. Stem Cell Reports
2018;10(4):1251–66. Epub
2018/03/13. doi: 10.1016/j.stemcr.2018.02.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stemcr.2018.02.001</ArticleId>
            <ArticleId IdType="pmc">PMC5998838</ArticleId>
            <ArticleId IdType="pubmed">29526735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kittler P, Krinsky-McHale SJ, Devenny DA. Sex differences in performance over 7 years on the Wechsler Intelligence Scale for Children--Revised among adults with intellectual disability. J Intellect Disabil Res
2004;48(Pt 2):114–22. Epub
2004/01/16. doi: 10.1111/j.1365-2788.2004.00500.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2788.2004.00500.x</ArticleId>
            <ArticleId IdType="pubmed">14723654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Sola S, de la Torre R, Sánchez-Benavides G, Benejam B, Cuenca-Royo A, Del Hoyo L, Rodríguez J, Catuara-Solarz S, Sanchez-Gutierrez J, Dueñas-Espin I, Hernandez G, Peña-Casanova J, Langohr K, Videla S, Blehaut H, Farre M, Dierssen M. A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials. Front Psychol
2015;6:708. Epub
2015/06/20. doi: 10.3389/fpsyg.2015.00708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fpsyg.2015.00708</ArticleId>
            <ArticleId IdType="pmc">PMC4455308</ArticleId>
            <ArticleId IdType="pubmed">26089807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franconi F, Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. Br J Pharmacol
2014;171(3):580–94. Epub
2013/08/29. doi: 10.1111/bph.12362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.12362</ArticleId>
            <ArticleId IdType="pmc">PMC3969074</ArticleId>
            <ArticleId IdType="pubmed">23981051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levenga J, Peterson DJ, Cain P, Hoeffer CA. Sleep Behavior and EEG Oscillations in Aged Dp(16)1Yey/+ Mice: A Down Syndrome Model. Neuroscience
2018;376:117–26. Epub
2018/02/20. doi: 10.1016/j.neuroscience.2018.02.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2018.02.009</ArticleId>
            <ArticleId IdType="pmc">PMC7255843</ArticleId>
            <ArticleId IdType="pubmed">29454635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodliffe JW, Olmos-Serrano JL, Aziz NM, Pennings JL, Guedj F, Bianchi DW, Haydar TF. Absence of Prenatal Forebrain Defects in the Dp(16)1Yey/+ Mouse Model of Down Syndrome. J Neurosci
2016;36(10):2926–44. Epub
2016/03/11. doi: 10.1523/jneurosci.2513-15.2016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/jneurosci.2513-15.2016</ArticleId>
            <ArticleId IdType="pmc">PMC4783496</ArticleId>
            <ArticleId IdType="pubmed">26961948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Capone G, Goyal P, Ares W, Lannigan E. Neurobehavioral disorders in children, adolescents, and young adults with Down syndrome. Am J Med Genet C Semin Med Genet
2006;142c(3):158–72. Epub
2006/07/14. doi: 10.1002/ajmg.c.30097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajmg.c.30097</ArticleId>
            <ArticleId IdType="pubmed">16838318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Godfrey M, Lee NR. Memory profiles in Down syndrome across development: a review of memory abilities through the lifespan. J Neurodev Disord
2018;10(1):5. Epub
2018/01/31. doi: 10.1186/s11689-017-9220-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s11689-017-9220-y</ArticleId>
            <ArticleId IdType="pmc">PMC5789527</ArticleId>
            <ArticleId IdType="pubmed">29378508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herault Y, Duchon A, Velot E, Marechal D, Brault V. The in vivo Down syndrome genomic library in mouse. Prog Brain Res
2012;197:169–97. Epub
2012/05/01. doi: 10.1016/b978-0-444-54299-1.00009-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/b978-0-444-54299-1.00009-1</ArticleId>
            <ArticleId IdType="pubmed">22541293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stasko MR, Costa AC. Experimental parameters affecting the Morris water maze performance of a mouse model of Down syndrome. Behav Brain Res
2004;154(1):1–17. Epub
2004/08/11. doi: 10.1016/j.bbr.2004.01.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbr.2004.01.012</ArticleId>
            <ArticleId IdType="pubmed">15302106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raveau M, Polygalov D, Boehringer R, Amano K, Yamakawa K, McHugh TJ. Alterations of in vivo CA1 network activity in Dp(16)1Yey Down syndrome model mice. Elife
2018;7. Epub
2018/02/28. doi: 10.7554/eLife.31543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.31543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aziz NM, Guedj F, Pennings JLA, Olmos-Serrano JL, Siegel A, Haydar TF, Bianchi DW. Lifespan analysis of brain development, gene expression and behavioral phenotypes in the Ts1Cje, Ts65Dn and Dp(16)1/Yey mouse models of Down syndrome. Dis Model Mech
2018;11(6). Epub
2018/05/03. doi: 10.1242/dmm.031013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dmm.031013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu T, Liu C, Belichenko P, Clapcote SJ, Li S, Pao A, Kleschevnikov A, Bechard AR, Asrar S, Chen R, Fan N, Zhou Z, Jia Z, Chen C, Roder JC, Liu B, Baldini A, Mobley WC, Yu YE. Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice. Brain Res
2010;1366:162–71. Epub
2010/10/12. doi: 10.1016/j.brainres.2010.09.107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainres.2010.09.107</ArticleId>
            <ArticleId IdType="pmc">PMC3027718</ArticleId>
            <ArticleId IdType="pubmed">20932954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campbell C, Landry O, Russo N, Flores H, Jacques S, Burack JA. Cognitive flexibility among individuals with Down syndrome: assessing the influence of verbal and nonverbal abilities. Am J Intellect Dev Disabil
2013;118(3):193–200. Epub
2013/06/06. doi: 10.1352/1944-7558-118.3.193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1352/1944-7558-118.3.193</ArticleId>
            <ArticleId IdType="pubmed">23734614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou T, Satake A, Ojha P, Kambayashi T. Cellular therapies supplement: the role of granulocyte macrophage colony-stimulating factor and dendritic cells in regulatory T-cell homeostasis and expansion. Transfusion
2011;51
Suppl 4:160s–8s. Epub
2011/12/07. doi: 10.1111/j.1537-2995.2011.03379.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1537-2995.2011.03379.x</ArticleId>
            <ArticleId IdType="pmc">PMC4122334</ArticleId>
            <ArticleId IdType="pubmed">22074627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rowin J, Thiruppathi M, Arhebamen E, Sheng J, Prabhakar BS, Meriggioli MN. Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve
2012;46(3):449–53. Epub
2012/08/22. doi: 10.1002/mus.23488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.23488</ArticleId>
            <ArticleId IdType="pmc">PMC3428740</ArticleId>
            <ArticleId IdType="pubmed">22907239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinhage T, Dabritz J, Brockhausen A, Wirth T, Bruckner M, Belz M, Foell D, Varga G. Granulocyte Macrophage Colony-Stimulating Factor-Activated CD39(+)/CD73(+) Murine Monocytes Modulate Intestinal Inflammation via Induction of Regulatory T Cells. Cell Mol Gastroenterol Hepatol
2015;1(4):433–49.e1.
Epub
2015/05/06. doi: 10.1016/j.jcmgh.2015.04.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcmgh.2015.04.005</ArticleId>
            <ArticleId IdType="pmc">PMC5301274</ArticleId>
            <ArticleId IdType="pubmed">28210690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hotta M, Yoshimura H, Satake A, Tsubokura Y, Ito T, Nomura S. GM-CSF therapy inhibits chronic graft-versus-host disease via expansion of regulatory T cells. Eur J Immunol
2019;49(1):179–91. Epub
2018/11/21. doi: 10.1002/eji.201847684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201847684</ArticleId>
            <ArticleId IdType="pubmed">30457669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheng JR, Muthusamy T, Prabhakar BS, Meriggioli MN. GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis. J Neuroimmunol
2011;240–241:65–73.
Epub
2011/11/22. doi: 10.1016/j.jneuroim.2011.10.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2011.10.010</ArticleId>
            <ArticleId IdType="pubmed">21186064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganesh BB, Cheatem DM, Sheng JR, Vasu C, Prabhakar BS. GM-CSF-induced CD11c+CD8a--dendritic cells facilitate Foxp3+ and IL-10+ regulatory T cell expansion resulting in suppression of autoimmune thyroiditis. Int Immunol
2009;21(3):269–82. Epub
2009/01/29. doi: 10.1093/intimm/dxn147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/intimm/dxn147</ArticleId>
            <ArticleId IdType="pmc">PMC2645781</ArticleId>
            <ArticleId IdType="pubmed">19174473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dabritz J, Weinhage T, Varga G, Wirth T, Walscheid K, Brockhausen A, Schwarzmaier D, Bruckner M, Ross M, Bettenworth D, Roth J, Ehrchen JM, Foell D. Reprogramming of monocytes by GM-CSF contributes to regulatory immune functions during intestinal inflammation. J Immunol
2015;194(5):2424–38. Epub
2015/02/06. doi: 10.4049/jimmunol.1401482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1401482</ArticleId>
            <ArticleId IdType="pubmed">25653427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhattacharya P, Thiruppathi M, Elshabrawy HA, Alharshawi K, Kumar P, Prabhakar BS. GM-CSF: An immune modulatory cytokine that can suppress autoimmunity. Cytokine
2015;75(2):261–71. Epub
2015/06/27. doi: 10.1016/j.cyto.2015.05.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2015.05.030</ArticleId>
            <ArticleId IdType="pmc">PMC4553090</ArticleId>
            <ArticleId IdType="pubmed">26113402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pellegrini FP, Marinoni M, Frangione V, Tedeschi A, Gandini V, Ciglia F, Mortara L, Accolla RS, Nespoli L. Down syndrome, autoimmunity and T regulatory cells. Clin Exp Immunol
2012;169(3):238–43. Epub
2012/08/07. doi: 10.1111/j.1365-2249.2012.04610.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2249.2012.04610.x</ArticleId>
            <ArticleId IdType="pmc">PMC3445000</ArticleId>
            <ArticleId IdType="pubmed">22861363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amr NH. Thyroid Disorders in Subjects with Down Syndrome: An Update. Acta Biomed
2018;89(1):132–9. Epub
2018/04/11. doi: 10.23750/abm.v89i1.7120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.23750/abm.v89i1.7120</ArticleId>
            <ArticleId IdType="pmc">PMC6357620</ArticleId>
            <ArticleId IdType="pubmed">29633736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aversa T, Crisafulli G, Zirilli G, De Luca F, Gallizzi R, Valenzise M. Epidemiological and clinical aspects of autoimmune thyroid diseases in children with Down’s syndrome. Ital J Pediatr
2018;44(1):39. Epub
2018/03/23. doi: 10.1186/s13052-018-0478-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13052-018-0478-9</ArticleId>
            <ArticleId IdType="pmc">PMC5863361</ArticleId>
            <ArticleId IdType="pubmed">29562915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vasu C, Dogan RN, Holterman MJ, Prabhakar BS. Selective induction of dendritic cells using granulocyte macrophage-colony stimulating factor, but not fms-like tyrosine kinase receptor 3-ligand, activates thyroglobulin-specific CD4+/CD25+ T cells and suppresses experimental autoimmune thyroiditis. J Immunol
2003;170(11):5511–22. Epub
2003/05/22. doi: 10.4049/jimmunol.170.11.5511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.170.11.5511</ArticleId>
            <ArticleId IdType="pubmed">12759428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gangi E, Vasu C, Cheatem D, Prabhakar BS. IL-10-producing CD4+CD25+ regulatory T cells play a critical role in granulocyte-macrophage colony-stimulating factor-induced suppression of experimental autoimmune thyroiditis. J Immunol
2005;174(11):7006–13. Epub
2005/05/21. doi: 10.4049/jimmunol.174.11.7006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.174.11.7006</ArticleId>
            <ArticleId IdType="pubmed">15905543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonucci F, Alpar A, Kacza J, Caleo M, Verderio C, Giani A, Martens H, Chaudhry FA, Allegra M, Grosche J, Michalski D, Erck C, Hoffmann A, Harkany T, Matteoli M, Hartig W. Cracking down on inhibition: selective removal of GABAergic interneurons from hippocampal networks. J Neurosci
2012;32(6):1989–2001. Epub
2012/02/11. doi: 10.1523/jneurosci.2720-11.2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/jneurosci.2720-11.2012</ArticleId>
            <ArticleId IdType="pmc">PMC3742881</ArticleId>
            <ArticleId IdType="pubmed">22323713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tremblay R, Lee S, Rudy B. GABAergic Interneurons in the Neocortex: From Cellular Properties to Circuits. Neuron
2016;91(2):260–92. Epub
2016/08/02. doi: 10.1016/j.neuron.2016.06.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2016.06.033</ArticleId>
            <ArticleId IdType="pmc">PMC4980915</ArticleId>
            <ArticleId IdType="pubmed">27477017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng X, Gu L, Sui N, Guo J, Liang J. Parvalbumin interneuron in the ventral hippocampus functions as a discriminator in social memory. Proc Natl Acad Sci U S A
2019;116(33):16583–92. Epub
2019/07/31. doi: 10.1073/pnas.1819133116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1819133116</ArticleId>
            <ArticleId IdType="pmc">PMC6697894</ArticleId>
            <ArticleId IdType="pubmed">31358646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buschmann IR, Busch HJ, Mies G, Hossmann KA. Therapeutic induction of arteriogenesis in hypoperfused rat brain via granulocyte-macrophage colony-stimulating factor. Circulation
2003;108(5):610–5. Epub
2003/07/02. doi: 10.1161/01.Cir.0000074209.17561.99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.Cir.0000074209.17561.99</ArticleId>
            <ArticleId IdType="pubmed">12835229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hossmann KA, Buschmann IR. Granulocyte-macrophage colony-stimulating factor as an arteriogenic factor in the treatment of ischaemic stroke. Expert Opin Biol Ther
2005;5(12):1547–56. Epub
2005/12/02. doi: 10.1517/14712598.5.12.1547.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/14712598.5.12.1547</ArticleId>
            <ArticleId IdType="pubmed">16318419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schneeloch E, Mies G, Busch HJ, Buschmann IR, Hossmann KA. Granulocyte-macrophage colony-stimulating factor-induced arteriogenesis reduces energy failure in hemodynamic stroke. Proc Natl Acad Sci U S A
2004;101(34):12730–5. Epub
2004/08/13. doi: 10.1073/pnas.0404880101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0404880101</ArticleId>
            <ArticleId IdType="pmc">PMC514662</ArticleId>
            <ArticleId IdType="pubmed">15306685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakagawa T, Suga S, Kawase T, Toda M. Intracarotid injection of granulocyte-macrophage colony-stimulating factor induces neuroprotection in a rat transient middle cerebral artery occlusion model. Brain Res
2006;1089(1):179–85. Epub
2006/05/09. doi: 10.1016/j.brainres.2006.03.059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainres.2006.03.059</ArticleId>
            <ArticleId IdType="pubmed">16678804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schabitz WR, Kruger C, Pitzer C, Weber D, Laage R, Gassler N, Aronowski J, Mier W, Kirsch F, Dittgen T, Bach A, Sommer C, Schneider A. A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF). J Cereb Blood Flow Metab
2008;28(1):29–43. doi: 10.1038/sj.jcbfm.9600496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.jcbfm.9600496</ArticleId>
            <ArticleId IdType="pubmed">17457367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schneider UC, Schilling L, Schroeck H, Nebe CT, Vajkoczy P, Woitzik J. Granulocyte-macrophage colony-stimulating factor-induced vessel growth restores cerebral blood supply after bilateral carotid artery occlusion. Stroke
2007;38(4):1320–8. doi: 10.1161/01.STR.0000259707.43496.71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.STR.0000259707.43496.71</ArticleId>
            <ArticleId IdType="pubmed">17332468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Todo K, Kitagawa K, Sasaki T, Omura-Matsuoka E, Terasaki Y, Oyama N, Yagita Y, Hori M. Granulocyte-macrophage colony-stimulating factor enhances leptomeningeal collateral growth induced by common carotid artery occlusion. Stroke
2008;39(6):1875–82. Epub
2008/04/05. doi: 10.1161/strokeaha.107.503433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/strokeaha.107.503433</ArticleId>
            <ArticleId IdType="pubmed">18388343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kong T, Choi JK, Park H, Choi BH, Snyder BJ, Bukhari S, Kim NK, Huang X, Park SR, Park HC, Ha Y. Reduction in programmed cell death and improvement in functional outcome of transient focal cerebral ischemia after administration of granulocyte-macrophage colony-stimulating factor in rats. Laboratory investigation. J Neurosurg
2009;111(1):155–63. doi: 10.3171/2008.12.JNS08172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2008.12.JNS08172</ArticleId>
            <ArticleId IdType="pubmed">19361262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theoret JK, Jadavji NM, Zhang M, Smith PD. Granulocyte macrophage colony-stimulating factor treatment results in recovery of motor function after white matter damage in mice. Eur J Neurosci
2016;43(1):17–24. Epub
2015/10/17. doi: 10.1111/ejn.13105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ejn.13105</ArticleId>
            <ArticleId IdType="pubmed">26474338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schallenberg M, Charalambous P, Thanos S. GM-CSF regulates the ERK1/2 pathways and protects injured retinal ganglion cells from induced death. Exp Eye Res
2009;89(5):665–77. Epub
2009/06/30. doi: 10.1016/j.exer.2009.06.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.exer.2009.06.008</ArticleId>
            <ArticleId IdType="pubmed">19560459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schallenberg M, Charalambous P, Thanos S. GM-CSF protects rat photoreceptors from death by activating the SRC-dependent signalling and elevating anti-apoptotic factors and neurotrophins. Graefes Arch Clin Exp Ophthalmol
2012;250(5):699–712. Epub
2012/02/03. doi: 10.1007/s00417-012-1932-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00417-012-1932-9</ArticleId>
            <ArticleId IdType="pubmed">22297538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Legacy J, Hanea S, Theoret J, Smith PD. Granulocyte macrophage colony-stimulating factor promotes regeneration of retinal ganglion cells in vitro through a mammalian target of rapamycin-dependent mechanism. J Neurosci Res
2013;91(6):771–9. Epub
2013/03/05. doi: 10.1002/jnr.23205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jnr.23205</ArticleId>
            <ArticleId IdType="pubmed">23456828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JK, Choi BH, Park HC, Park SR, Kim YS, Yoon SH, Park HS, Kim EY, Ha Y. Effects of GM-CSF on the neural progenitor cells. Neuroreport
2004;15(14):2161–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15371725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang X, Choi JK, Park SR, Ha Y, Park H, Yoon SH, Park HC, Park JO, Choi BH. GM-CSF inhibits apoptosis of neural cells via regulating the expression of apoptosis-related proteins. Neurosci Res
2007;58(1):50–7. Epub
2007/03/03. doi: 10.1016/j.neures.2007.01.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neures.2007.01.015</ArticleId>
            <ArticleId IdType="pubmed">17331604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi JK, Choi BH, Ha Y, Park H, Yoon SH, Park HC, Park SR. Signal transduction pathways of GM-CSF in neural cell lines. Neurosci Lett
2007;420(3):217–22. Epub
2007/06/09. doi: 10.1016/j.neulet.2007.03.065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neulet.2007.03.065</ArticleId>
            <ArticleId IdType="pubmed">17556097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi JK, Kim KH, Park H, Park SR, Choi BH. Granulocyte macrophage-colony stimulating factor shows anti-apoptotic activity in neural progenitor cells via JAK/STAT5-Bcl-2 pathway. Apoptosis
2011;16(2):127–34. Epub
2010/11/06. doi: 10.1007/s10495-010-0552-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10495-010-0552-2</ArticleId>
            <ArticleId IdType="pubmed">21052840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi JK, Kim KH, Park SR, Choi BH. Granulocyte macrophage colony-stimulating factor shows anti-apoptotic activity via the PI3K-NF-kappaB-HIF-1alpha-survivin pathway in mouse neural progenitor cells. Mol Neurobiol
2014;49(2):724–33. Epub
2013/09/12. doi: 10.1007/s12035-013-8550-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12035-013-8550-3</ArticleId>
            <ArticleId IdType="pubmed">24022164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kruger C, Laage R, Pitzer C, Schabitz WR, Schneider A. The hematopoietic factor GM-CSF (granulocyte-macrophage colony-stimulating factor) promotes neuronal differentiation of adult neural stem cells in vitro. BMC Neurosci
2007;8:88. doi: 10.1186/1471-2202-8-88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2202-8-88</ArticleId>
            <ArticleId IdType="pmc">PMC2233634</ArticleId>
            <ArticleId IdType="pubmed">17953750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guthridge MA, Powell JA, Barry EF, Stomski FC, McClure BJ, Ramshaw H, Felquer FA, Dottore M, Thomas DT, To B, Begley CG, Lopez AF. Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. Embo j
2006;25(3):479–89. Epub
2006/01/27. doi: 10.1038/sj.emboj.7600948.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.emboj.7600948</ArticleId>
            <ArticleId IdType="pmc">PMC1383532</ArticleId>
            <ArticleId IdType="pubmed">16437163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McLay RN, Kimura M, Banks WA, Kastin AJ. Granulocyte-macrophage colony-stimulating factor crosses the blood--brain and blood--spinal cord barriers. Brain
1997;120 (Pt 11):2083–91. Epub
1997/12/16. doi: 10.1093/brain/120.11.2083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/120.11.2083</ArticleId>
            <ArticleId IdType="pubmed">9397023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sawada M, Itoh Y, Suzumura A, Marunouchi T. Expression of cytokine receptors in cultured neuronal and glial cells. Neurosci Lett
1993;160(2):131–4. Epub
1993/10/01. doi: 10.1016/0304-3940(93)90396-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0304-3940(93)90396-3</ArticleId>
            <ArticleId IdType="pubmed">8247342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baldwin GC, Benveniste EN, Chung GY, Gasson JC, Golde DW. Identification and characterization of a high-affinity granulocyte-macrophage colony-stimulating factor receptor on primary rat oligodendrocytes. Blood
1993;82(11):3279–82. Epub
1993/12/01.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8241500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krieger M, Both M, Kranig SA, Pitzer C, Klugmann M, Vogt G, Draguhn A, Schneider A. The hematopoietic cytokine granulocyte-macrophage colony stimulating factor is important for cognitive functions. Sci Rep
2012;2:697. doi: 10.1038/srep00697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep00697</ArticleId>
            <ArticleId IdType="pmc">PMC3458247</ArticleId>
            <ArticleId IdType="pubmed">23019518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J, Kim NK, Park SR, Choi BH. GM-CSF Enhances Mobilization of Bone Marrow Mesenchymal Stem Cells via a CXCR4-Medicated Mechanism. Tissue Eng Regen Med
2019;16(1):59–68. Epub
2019/03/01. doi: 10.1007/s13770-018-0163-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13770-018-0163-5</ArticleId>
            <ArticleId IdType="pmc">PMC6361095</ArticleId>
            <ArticleId IdType="pubmed">30815351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park SR, Cho A, Kim JW, Lee HY, Hong IS. A Novel Endogenous Damage Signal, CSF-2, Activates Multiple Beneficial Functions of Adipose Tissue-Derived Mesenchymal Stem Cells. Mol Ther
2019;27(6):1087–100. Epub
2019/04/10. doi: 10.1016/j.ymthe.2019.03.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymthe.2019.03.010</ArticleId>
            <ArticleId IdType="pmc">PMC6554530</ArticleId>
            <ArticleId IdType="pubmed">30962162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakari-Khiavi F, Dolati S, Chakari-Khiavi A, Abbaszadeh H, Aghebati-Maleki L, Pourlak T, Mehdizadeh A, Yousefi M. Prospects for the application of mesenchymal stem cells in Alzheimer’s disease treatment. Life Sci
2019;231:116564. Epub
2019/06/17. doi: 10.1016/j.lfs.2019.116564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2019.116564</ArticleId>
            <ArticleId IdType="pubmed">31202840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge M, Zhang Y, Hao Q, Zhao Y, Dong B. Effects of mesenchymal stem cells transplantation on cognitive deficits in animal models of Alzheimer’s disease: A systematic review and meta-analysis. Brain Behav
2018;8(7):e00982. Epub
2018/06/08. doi: 10.1002/brb3.982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/brb3.982</ArticleId>
            <ArticleId IdType="pmc">PMC6043701</ArticleId>
            <ArticleId IdType="pubmed">29877067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang Y, Gao H, Yuan H, Xu H, Tian M, Du G, Xie W. Amelioration of postoperative cognitive dysfunction in mice by mesenchymal stem cell-conditioned medium treatments is associated with reduced inflammation, oxidative stress and increased BDNF expression in brain tissues. Neurosci Lett
2019;709:134372. Epub
2019/07/12. doi: 10.1016/j.neulet.2019.134372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neulet.2019.134372</ArticleId>
            <ArticleId IdType="pubmed">31295540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maldonado-Lasunción I, Verhaagen J, Oudega M. Mesenchymal Stem Cell-Macrophage Choreography Supporting Spinal Cord Repair. Neurotherapeutics
2018;15(3):578–87. Epub
2018/05/08. doi: 10.1007/s13311-018-0629-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13311-018-0629-0</ArticleId>
            <ArticleId IdType="pmc">PMC6095786</ArticleId>
            <ArticleId IdType="pubmed">29728851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendes Filho D, Ribeiro PDC, Oliveira LF, de Paula DRM, Capuano V, de Assunção TSF, da Silva VJD. Therapy With Mesenchymal Stem Cells in Parkinson Disease: History and Perspectives. Neurologist
2018;23(4):141–7. Epub
2018/06/29. doi: 10.1097/nrl.0000000000000188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/nrl.0000000000000188</ArticleId>
            <ArticleId IdType="pubmed">29953040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakazaki M, Sasaki M, Kataoka-Sasaki Y, Oka S, Suzuki J, Sasaki Y, Nagahama H, Hashi K, Kocsis JD, Honmou O. Intravenous infusion of mesenchymal stem cells improves impaired cognitive function in a cerebral small vessel disease model. Neuroscience
2019;408:361–77. Epub
2019/04/19. doi: 10.1016/j.neuroscience.2019.04.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2019.04.018</ArticleId>
            <ArticleId IdType="pubmed">30999031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials
2019;20(1):263. Epub
2019/05/11. doi: 10.1186/s13063-019-3346-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13063-019-3346-z</ArticleId>
            <ArticleId IdType="pmc">PMC6507027</ArticleId>
            <ArticleId IdType="pubmed">31072380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology
1996;47(2):425–32. Epub
1996/08/01. doi: 10.1212/wnl.47.2.425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/wnl.47.2.425</ArticleId>
            <ArticleId IdType="pubmed">8757015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarkowski E, Wallin A, Regland B, Blennow K, Tarkowski A. Local and systemic GM-CSF increase in Alzheimer’s disease and vascular dementia. Acta Neurol Scand
2001;103(3):166–74. Epub
2001/03/10. doi: 10.1034/j.1600-0404.2001.103003166.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1034/j.1600-0404.2001.103003166.x</ArticleId>
            <ArticleId IdType="pubmed">11240564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel NS, Paris D, Mathura V, Quadros AN, Crawford FC, Mullan MJ. Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer’s disease. J Neuroinflammation
2005;2(1):9. Epub
2005/03/15. doi: 10.1186/1742-2094-2-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1742-2094-2-9</ArticleId>
            <ArticleId IdType="pmc">PMC555557</ArticleId>
            <ArticleId IdType="pubmed">15762998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Volmar CH, Ait-Ghezala G, Frieling J, Paris D, Mullan MJ. The granulocyte macrophage colony stimulating factor (GM-CSF) regulates amyloid beta (Abeta) production. Cytokine
2008;42(3):336–44. Epub
2008/04/25. doi: 10.1016/j.cyto.2008.03.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2008.03.007</ArticleId>
            <ArticleId IdType="pubmed">18434187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M. Cognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol
2008;65(7):896–905. Epub
2008/05/14. doi: 10.1001/archneur.2008.65.7.nct70006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.2008.65.7.nct70006</ArticleId>
            <ArticleId IdType="pmc">PMC2925195</ArticleId>
            <ArticleId IdType="pubmed">18474729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ADAPT_FS_Research_Group. Follow-up evaluation of cognitive function in the randomized Alzheimer’s Disease Anti-inflammatory Prevention Trial and its Follow-up Study. Alzheimers Dement
2015;11(2):216–25.e1.
Epub
2014/07/16. doi: 10.1016/j.jalz.2014.03.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jalz.2014.03.009</ArticleId>
            <ArticleId IdType="pmc">PMC4287453</ArticleId>
            <ArticleId IdType="pubmed">25022541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed MM, Johnson NR, Boyd TD, Coughlan CM, Chial HJ, Potter H. Innate Immune System Activation and Neuroinflammation in Down Syndrome and Neurodegeneration: Therapeutic Targets or Partners?
Front Aging Neurosci
2021. Epub
2021/09/16. doi: 10.3389/fnagi.2021.718426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnagi.2021.718426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Domenico F, Coccia R, Cocciolo A, Murphy MP, Cenini G, Head E, Butterfield DA, Giorgi A, Schinina ME, Mancuso C, Cini C, Perluigi M. Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer’s disease neuropathology: redox proteomics analysis of human brain. Biochim Biophys Acta
2013;1832(8):1249–59. Epub
2013/04/23. doi: 10.1016/j.bbadis.2013.04.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2013.04.013</ArticleId>
            <ArticleId IdType="pmc">PMC3940071</ArticleId>
            <ArticleId IdType="pubmed">23603808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol
2010;119(1):7–35. Epub
2009/12/17. doi: 10.1007/s00401-009-0619-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-009-0619-8</ArticleId>
            <ArticleId IdType="pmc">PMC2799634</ArticleId>
            <ArticleId IdType="pubmed">20012068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki A, Stern SA, Bozdagi O, Huntley GW, Walker RH, Magistretti PJ, Alberini CM. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell
2011;144(5):810–23. Epub
2011/03/08. doi: 10.1016/j.cell.2011.02.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.02.018</ArticleId>
            <ArticleId IdType="pmc">PMC3073831</ArticleId>
            <ArticleId IdType="pubmed">21376239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bezzi P, Volterra A. Astrocytes: powering memory. Cell
2011;144(5):644–5. Epub
2011/03/08. doi: 10.1016/j.cell.2011.02.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.02.027</ArticleId>
            <ArticleId IdType="pubmed">21376229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diniz LP, Tortelli V, Garcia MN, Araujo AP, Melo HM, Silva GS, Felice FG, Alves-Leon SV, Souza JM, Romao LF, Castro NG, Gomes FC. Astrocyte transforming growth factor beta 1 promotes inhibitory synapse formation via CaM kinase II signaling. Glia
2014;62(12):1917–31. Epub
2014/07/22. doi: 10.1002/glia.22713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/glia.22713</ArticleId>
            <ArticleId IdType="pubmed">25042347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stogsdill JA, Ramirez J, Liu D, Kim YH, Baldwin KT, Enustun E, Ejikeme T, Ji RR, Eroglu C. Astrocytic neuroligins control astrocyte morphogenesis and synaptogenesis. Nature
2017;551(7679):192–7. Epub
2017/11/10. doi: 10.1038/nature24638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature24638</ArticleId>
            <ArticleId IdType="pmc">PMC5796651</ArticleId>
            <ArticleId IdType="pubmed">29120426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furman JL, Sama DM, Gant JC, Beckett TL, Murphy MP, Bachstetter AD, Van Eldik LJ, Norris CM. Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer’s disease. J Neurosci
2012;32(46):16129–40. Epub
2012/11/16. doi: 10.1523/jneurosci.2323-12.2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/jneurosci.2323-12.2012</ArticleId>
            <ArticleId IdType="pmc">PMC3506017</ArticleId>
            <ArticleId IdType="pubmed">23152597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lioy DT, Garg SK, Monaghan CE, Raber J, Foust KD, Kaspar BK, Hirrlinger PG, Kirchhoff F, Bissonnette JM, Ballas N, Mandel G. A role for glia in the progression of Rett’s syndrome. Nature
2011;475(7357):497–500. Epub
2011/07/01. doi: 10.1038/nature10214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature10214</ArticleId>
            <ArticleId IdType="pmc">PMC3268776</ArticleId>
            <ArticleId IdType="pubmed">21716289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarasov VV, Svistunov AA, Chubarev VN, Sologova SS, Mukhortova P, Levushkin D, Somasundaram SG, Kirkland CE, Bachurin SO, Aliev G. Alterations of Astrocytes in the Context of Schizophrenic Dementia. Front Pharmacol
2019;10:1612. Epub
2020/03/03. doi: 10.3389/fphar.2019.01612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2019.01612</ArticleId>
            <ArticleId IdType="pmc">PMC7020441</ArticleId>
            <ArticleId IdType="pubmed">32116664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bondi H, Bortolotto V, Canonico PL, Grilli M. Complex and regional-specific changes in the morphological complexity of GFAP(+) astrocytes in middle-aged mice. Neurobiol Aging
2021;100:59–71. Epub
2021/01/26. doi: 10.1016/j.neurobiolaging.2020.12.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2020.12.018</ArticleId>
            <ArticleId IdType="pubmed">33493951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanaumi T, Milenkovic I, Adle-Biassette H, Aronica E, Kovacs GG. Non-neuronal cell responses differ between normal and Down syndrome developing brains. Int J Dev Neurosci
2013;31(8):796–803. Epub
2013/10/12. doi: 10.1016/j.ijdevneu.2013.09.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijdevneu.2013.09.011</ArticleId>
            <ArticleId IdType="pubmed">24113258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodison KL, Parhad IM, White CL III, Sima AAF, Clark AW. Neuronal and Glial Gene Expression in Neocortex of Down’s Syndrome and Alzheimer’s Disease. Journal of Neuropathology &amp; Experimental Neurology
1993;52(3):192–8. doi: 10.1097/00005072-199305000-00002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00005072-199305000-00002</ArticleId>
            <ArticleId IdType="pubmed">8492138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang X, Kim JM, Kong TH, Park SR, Ha Y, Kim MH, Park H, Yoon SH, Park HC, Park JO, Min BH, Choi BH. GM-CSF inhibits glial scar formation and shows long-term protective effect after spinal cord injury. J Neurol Sci
2009;277(1–2):87–97. Epub
2008/11/27. doi: 10.1016/j.jns.2008.10.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2008.10.022</ArticleId>
            <ArticleId IdType="pubmed">19033079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung J, Kim MH, Yoon YJ, Kim KH, Park SR, Choi BH. Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on glial scar formation after spinal cord injury in rats. J Neurosurg Spine
2014;21(6):966–73. Epub
2014/10/04. doi: 10.3171/2014.8.Spine131090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2014.8.Spine131090</ArticleId>
            <ArticleId IdType="pubmed">25279652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serre-Miranda C, Roque S, Santos NC, Costa P, Sousa N, Palha JA, Correia-Neves M. Cognition Is Associated With Peripheral Immune Molecules in Healthy Older Adults: A Cross-Sectional Study. Front Immunol
2020;11:2045. Epub
2020/09/29. doi: 10.3389/fimmu.2020.02045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.02045</ArticleId>
            <ArticleId IdType="pmc">PMC7493640</ArticleId>
            <ArticleId IdType="pubmed">32983153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frasca D, Blomberg BB. Inflammaging decreases adaptive and innate immune responses in mice and humans. Biogerontology
2016;17(1):7–19. Epub
2015/04/30. doi: 10.1007/s10522-015-9578-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10522-015-9578-8</ArticleId>
            <ArticleId IdType="pmc">PMC4626429</ArticleId>
            <ArticleId IdType="pubmed">25921609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashraf-Ganjouei A, Moradi K, Bagheri S, Aarabi MH. The association between systemic inflammation and cognitive performance in healthy adults. J Neuroimmunol
2020;345:577272. Epub
2020/06/14. doi: 10.1016/j.jneuroim.2020.577272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2020.577272</ArticleId>
            <ArticleId IdType="pubmed">32534387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trollor JN, Smith E, Agars E, Kuan SA, Baune BT, Campbell L, Samaras K, Crawford J, Lux O, Kochan NA, Brodaty H, Sachdev P. The association between systemic inflammation and cognitive performance in the elderly: the Sydney Memory and Ageing Study. Age (Dordr)
2012;34(5):1295–308. Epub
2011/08/20. doi: 10.1007/s11357-011-9301-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11357-011-9301-x</ArticleId>
            <ArticleId IdType="pmc">PMC3448981</ArticleId>
            <ArticleId IdType="pubmed">21853262</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
